Marcella Ruddy

Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million.

Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021.

AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA.